How and why the adenosine A 2A receptor became a target for Parkinson's disease therapy.
Autor: | Jenner P; Institute of Pharmaceutical Sciences, King's College London, London, United Kingdom. Electronic address: peter.jenner@kcl.ac.uk., Kanda T; Kyowa Kirin Co., Ltd., Otemachi. Chiyoda-ku, Tokyo, Japan., Mori A; SNLD Ltd., Akashi-sho, Chuo-ku, Tokyo, Japan. |
---|---|
Jazyk: | angličtina |
Zdroj: | International review of neurobiology [Int Rev Neurobiol] 2023; Vol. 170, pp. 73-104. Date of Electronic Publication: 2023 May 14. |
DOI: | 10.1016/bs.irn.2023.04.005 |
Abstrakt: | Dopaminergic therapy for Parkinson's disease has revolutionised the treatment of the motor symptoms of the illness. However, it does not alleviate all components of the motor deficits and has only limited effects on non-motor symptoms. For this reason, alternative non-dopaminergic approaches to treatment have been sought and the adenosine A (Copyright © 2023. Published by Elsevier Inc.) |
Databáze: | MEDLINE |
Externí odkaz: |